Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
1 other identifier
observational
500
1 country
1
Brief Summary
The China Alliance for Type 1 Diabetes (CAT1D) is committed to exploring and implementing the model of graded diagnosis and treatment of type 1 diabetes and comprehensive management of outpatient service, carrying out a series of educational activities for patients, and cooperating in the development of multi-center prospective clinical research on type 1 diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2016
CompletedFirst Submitted
Initial submission to the registry
September 2, 2019
CompletedFirst Posted
Study publicly available on registry
September 20, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2027
April 21, 2023
April 1, 2023
11 years
September 2, 2019
April 19, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
changes in serum hemoglobin A1c level
A1c reflects the average blood glucose level in the past 3 months.
Baseline and every up to 12 weeks afterwards
Secondary Outcomes (11)
changes in Time in range (TIR)
Baseline and every up to 12 weeks afterwards
C-peptide
Baseline and every up to 12 weeks afterwards
Change in titer of autoantibodies
Baseline and every up to 12 weeks afterwards
Fasting blood glucose
Baseline and every up to 12 weeks afterwards
Systolic blood pressure
Baseline and every up to 12 weeks afterwards
- +6 more secondary outcomes
Eligibility Criteria
type 1 diabetes patients
You may qualify if:
- Individuals diagnosed with Type 1 Diabetes according to the 1999 World Health Organization report
- Written informed consent from the patient or family representative;
- Individuals who own smartphone and are capable of using wechat or apps
You may not qualify if:
- Non-t1dm patients with autoimmune polyendocrine adenopathy syndrome (APS) are the first disease
- With mental disorders
- Have any other condition or disease that may hamper from compliance with the protocol or complication of the trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha, Hunan, 410011, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor,Institute of Metabolism and Endocrinology, The Second Xiangya Hospital and the Diabetes Center, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, National Clinical Research Center for Metabolic Diseases.
Study Record Dates
First Submitted
September 2, 2019
First Posted
September 20, 2019
Study Start
September 1, 2016
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2027
Last Updated
April 21, 2023
Record last verified: 2023-04